Full Press Release Details
Anavex announces director resignation
Palo Alto, CA -- March 27, 2012 --
Anavex Life Sciences Corp. ( Anavex ) (OTCBB: AVXL) reports the departure of Dr.
George Tidmarsh as executive director. Dr. Tidmarsh resigned to devote time to
other professional responsibilities. Anavex s Board of Directors would like to
thank Dr. Tidmarsh for his contributions to the company and wish him well in his
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a specialty
pharmaceutical company engaged in the discovery and development of novel drug
candidates for the treatment of neurological diseases and cancer. The Anavex
proprietary SIGMACEPTOR Discovery Platform involves the rational design of drug
compounds targeted to specific receptors involved in the modulation of multiple
cellular biochemical signaling pathways.
The SIGMACEPTOR -N program involves the development of novel
drug candidates that target neurological and neurodegenerative diseases
(Alzheimer's disease, epilepsy, depression, pain). The company's lead drug
candidates exhibit high affinity for sigma receptors, which have been
extensively documented as potentially valuable drug targets and have
demonstrated anti-amnesic and neuroprotective properties. A portfolio of back-up
compounds to ANAVEX 2-73 are also in development.
Anavex is a publicly traded company under the symbol AVXL.
| For Further Information |
| Anavex Life Sciences Corp. |
| Research & Business Development |
| Email: info@anavex.com |
| Shareholder & Media Relations |
| Toll-free: 1-866-505-2895 |
| Outside North America: +1 (416) 489-0092 |
| Email: ir@anavex.com |
| www.anavex.com |